Considering the high-frequency somatic hypermethylation of MLH1 in CRC and endometrial cases, before germline testing and genetic evaluation, hypermethylation of the MLH1 promoter should be excluded either by direct evaluation or by assessing the presence of the somatic BRAF V600E mutation, which, as a result, acquires negative predictive values in the case of CRC [65,79]. This evidence concerns the gene BRAF and colorectal carcinoma.